Compare FirstEnergy Corp. (FE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Moderna, Inc. — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.95B), while Moderna, Inc. trades at $198.1 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 3× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays a 4.15% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Moderna, Inc. for 59 Days on average.
| FE | MRNA | |
|---|---|---|
Market Cap | $25.95B | $78.65B |
Volume | 5,643,833 | 37,373,437 |
Sector | Utilities | Health |
52-Week High | $51.91 | $203.46 |
52-Week Low | $43.04 | $22.36 |
Typical Hold Time | 71 Days | 59 Days |
Enterprise Value | $54.87B | $74.80B |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% today, with a bullish technical signal but mixed earnings history. Revenue grew to $15.09B in 2025, with a net income margin of 6.86%, while valuation ratios like P/E of 23.84 and P/S of 1.63 suggest moderate pricing. Recent news highlights dividend declarations and a $36B Energize365 investment plan, supporting long-term growth amid rising data-center demand.
Outlook is positive with a consensus price target of $52.80, implying 18% upside, but risks include high debt levels and volatile cash flows. Analyst sentiment is mixed with 43% buy ratings, while institutional ownership trends show recent stake increases, indicating cautious optimism for steady utility returns.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
